Molecular Insight Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
September 22 2008 - 8:00AM
Business Wire
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced
today that David S. Barlow, Chairman and Chief Executive Officer of
Molecular Insight Pharmaceuticals, will present at the upcoming UBS
Global Life Sciences Conference on Wednesday, September 24, 2008.
During his presentation, Mr. Barlow will provide an overview of the
Company and its pipeline of molecular imaging radiopharmaceutical
and targeted molecular radiotherapeutic candidates. The
presentation will take place at 12:00 p.m. Eastern Time in Ballroom
D, Carnegie Hall, of the Grand Hyatt New York hotel in New York,
New York. The presentation will be webcast live at: www.ibb.ubs.com
and will be archived until October 25, 2008. To access the live
webcast, click the "Conferences" icon in the center right of the
webpage and follow the link for the webcast next to
the�"Global�Life Sciences� Conference heading. The webcast will
also be available in the Investor Relations section of the
Molecular Insight Pharmaceuticals website at
www.molecularinsight.com. About Molecular Insight Pharmaceuticals,
Inc. Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a
biopharmaceutical company specializing in the emerging field of
molecular medicine, applying innovations in the identification and
targeting of disease at the molecular level to improve healthcare
for patients with life-threatening diseases. The Company is focused
on discovering, developing and commercializing innovative molecular
imaging radiopharmaceuticals and targeted molecular
radiotherapeutics with initial applications in the areas of
cardiology and oncology. Molecular Insight�s lead molecular imaging
radiopharmaceutical product candidate, Zemiva�, is being developed
for the diagnosis of cardiac ischemia, or insufficient blood flow
to the heart. The Company�s imaging candidate, Trofex�, is in
development for the detection of metastatic prostate cancer.
Molecular Insight�s lead molecular radiotherapeutic product
candidates, Azedra� and Onalta�, are being developed for detection
and treatment of cancer. In addition, the Company has a growing
pipeline of product candidates resulting from application of its
proprietary platform technologies to new and existing compounds.
Molecular Insight Pharmaceuticals is based in Cambridge,
Massachusetts and its website address is: www.molecularinsight.com.
Forward-Looking Statements Statements in this release that are not
strictly historical in nature constitute "forward-looking
statements." Such statements include, but are not limited to,
statements about the development of AzedraTM, OnaltaTM, ZemivaTM,
Trofex� and our other product candidates. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other factors that may cause the actual results of Molecular
Insight to be materially different from historical results or from
any results expressed or implied by such forward-looking
statements. These factors include, but are not limited to, risks
and uncertainties related to the progress, timing, cost, and
results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for product
candidates; competition from other pharmaceutical or biotechnology
companies; and the additional risks discussed in filings with the
Securities and Exchange Commission. All forward-looking statements
are qualified in their entirety by this cautionary statement, and
Molecular Insight undertakes no obligation to revise or update this
news release to reflect events or circumstances after the date
hereof.
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From May 2024 to Jun 2024
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Jun 2023 to Jun 2024